FibroBiologics advances bone marrow organoid platform for cancer and immune therapies

FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company, announced significant advancements in its Bone Marrow Organoid (BMO) platform, which may offer new treatment options for hematopoietic cancers and age-related immune decline. The company reported that pre-IND animal trials demonstrated that transplantation of BMOs into a xenografted melanoma mouse model significantly reduced tumor size. Additionally, the […] The post FibroBiologics advances bone marrow organoid platform for cancer and immune therapies appeared first on Longevity.Technology.